ExodusPoint Capital Management LP, a prominent institutional investor, has significantly increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the first quarter of this year, as stated in the company’s recent 13F filing with the Securities and Exchange Commission (SEC). The investment firm now owns 1,221,681 shares of BioCryst Pharmaceuticals’ stock after acquiring an additional 1,199,839 shares during the quarter. This increase represents a staggering growth of 5,493.3% in ExodusPoint Capital Management’s position. In terms of value, these holdings are estimated to be worth $10,189,000 based on the most recent filing.
BioCryst Pharmaceuticals last released its quarterly earnings results on August 3rd. During this period, the biotechnology company reported earnings per share (EPS) of ($0.24), surpassing analysts’ consensus estimates by $0.01. Despite missing revenue expectations slightly with $81.01 million compared to the consensus estimate of $81.42 million, BioCryst Pharmaceuticals demonstrated a notable year-over-year growth rate of 24.2% in terms of revenue generation for the quarter. In the same quarter last year, the company had posted an EPS of ($0.32). Analysts predict that for the current fiscal year, BioCryst Pharmaceuticals is expected to post an EPS of -0.96.
In another update related to insider trading activities at BioCryst Pharmaceuticals, Director Machelle Sanders sold 4,000 shares on June 15th for approximately $31,920 at an average price per share of $7.98. Following this transaction, Sanders now holds 25,611 shares in the company valued at around $204,375.
Overall ownership by insiders stands at approximately 4.40%, indicating their continued commitment and involvement in BioCryst Pharmaceuticals’ activities.
Investors and market analysts closely scrutinize 13F filings, earnings announcements, and insider trading activities to assess the financial health and growth prospects of companies. ExodusPoint Capital Management’s significant increase in its investment in BioCryst Pharmaceuticals underscores their confidence in the biotechnology firm’s potential.
BioCryst Pharmaceuticals is a leading player in the biotechnology industry, dedicated to discovering, developing, and commercializing innovative treatments for rare diseases. They employ cutting-edge science and technology to address unmet medical needs. With a focus on small molecule drug therapies, BioCryst Pharmaceuticals aims to improve patients’ lives by providing effective solutions for debilitating conditions.
As of August 26, 2023, investors continue to monitor BioCryst Pharmaceuticals’ latest developments as they anticipate future growth opportunities within the biotech sector. The company’s commitment to advancing healthcare through scientific innovation positions it as a key player in the race for breakthrough therapies.
Disclosure procedures facilitated by regulatory bodies such as the SEC ensure transparency by requiring companies and executives to disclose relevant information about their stock transactions. Such disclosures enable market participants to make informed decisions based on accurate data.
Investors should remain attentive to any further updates related to institutional investors’ positions, quarterly earnings reports, revenue figures, and insider trading activities at BioCryst Pharmaceuticals. These developments may provide valuable insights into the company’s financial performance and future prospects within the competitive biotechnology landscape
BioCryst Pharmaceuticals, Inc.
BCRX
Neutral
Updated on: 07/12/2023
Weak 
DCF: Strong Buy 
BioCryst Pharmaceuticals Attracts Interest from Major Institutional Investors
August 26, 2023 – BioCryst Pharmaceuticals, a leading biotechnology company, has recently seen changes in its investor positions. Rhumbline Advisers, one of the major investors, increased its stake in the company by 0.8% in the first quarter. This move resulted in Rhumbline Advisers now owning 311,069 shares of BioCryst Pharmaceuticals’ stock, valued at $2.59 million after purchasing an additional 2,538 shares in the last quarter.
Another significant investor, Commonwealth Equity Services LLC, also raised its holdings in BioCryst Pharmaceuticals by 3.8% during the same period. The company now owns 160,599 shares of the biotech firm’s stock worth $1.34 million after acquiring an additional 5,900 shares.
Citigroup Inc. saw an even more substantial increase in its holdings with a staggering 93.3% growth in the first quarter. The financial institution now owns 659,467 shares of BioCryst Pharmaceuticals’ stock worth $5.50 million after purchasing an additional 318,249 shares during the last quarter.
E Fund Management Co. Ltd., yet another institutional investor in BioCryst Pharmaceuticals, lifted its holdings by 15.7% during the first quarter. The company acquired an additional 6,330 shares and now owns a total of 46,585 shares worth $389,000.
In addition to these changes among large investors’ positions in BioCryst Pharmaceuticals’ stock was Landscape Capital Management L.L.C., acquiring a new stake worth approximately $156,000.
It is important to note that institutional investors currently own nearly 89.59% of BioCryst Pharmaceuticals’ stock.
Moving on to trading activities on Friday (August 25), NASDAQ:BCRX traded down $0.05 during regular trading hours and reached $7.19 per share. Within that day, the company had a trading volume of 291,928 shares, compared to its average volume of 2,812,530. BioCryst Pharmaceuticals’ stock has a 50-day moving average of $7.19 and a two-hundred day moving average of $8.08. Over the past year, the stock’s lowest point was $6.62 and its highest point reached $15.00.
Various equities research analysts have recently provided insights on BCRX shares. Bank of America upgraded its rating from “neutral” to “buy” and set a target price of $10.00 for the company in July. Royal Bank of Canada also increased its target price on BioCryst Pharmaceuticals from $8.00 to $9.00 while maintaining a “sector perform” rating in early August.
StockNews.com initiated coverage on BioCryst Pharmaceuticals with a “hold” rating later in August. Similarly, Needham & Company LLC reiterated a “buy” rating with a revised price target of $12.00 (originally set at $14.00) on shares of BioCryst Pharmaceuticals.
Jefferies Financial Group went further by upgrading their rating from “hold” to “buy” and setting a price target of $11.00 for the company in early August.
Based on aggregated ratings from Bloomberg analysts, BioCryst Pharmaceuticals currently holds an average rating of “Moderate Buy” with a consensus target price of $13.50.
For more detailed analysis on BioCryst Pharmaceuticals’ latest developments and prospects, please refer to our comprehensive report available on our website.
About BioCryst Pharmaceuticals:
BioCryst Pharmaceuticals is a leading biotechnology company known for its innovative approach in developing novel therapeutics for rare genetic diseases and viral infections. With cutting-edge research capabilities and strategic partnerships, the company continues to be at the forefront of advancing medical breakthroughs that enhance patient outcomes and quality of life.
Discussion about this post